‘Report Predicts Asthma and COPD Drug Revenues Will Reach $43.8BN in 2015′ Says visiongain

LONDON, August 8, 2011 -

www.visiongain.com/Report/658/Asthma-and-COPD-Therapies-World-Market-2011-2021

A new report by visiongain, a London-based business information company, predicts that world asthma and COPD drug revenues will reach $43.8bnin 2015. That market generated $32.1bn in 2010, according to Asthma and COPD Therapies: World Market 2011-2021, published in August 2011.

Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory disorders characterised by variable airflow obstruction and airway hyper-responsiveness to a variety of intrinsic, genetic and environmental stimuli. Those disorders are one of the leading causes of disability and death. Their prevalence and incidence are increasing worldwide.  

At present, drug therapies aim for management of those disorders by use of inhaled corticosteroids (ICs), short and long-acting β-agonists (SABAs/LABAs) and combination drugs. The asthma and COPD drug market is large, with six of the top ten drugs being blockbusters. The top three products had combined sales of $17.45 bn in 2010. Those drugs are GSK’s Seretide/Advair, Merck’s Singulair and Boehringer Ingelheim’s Spiriva.

Several of the blockbuster treatments will lose patent protection this decade. Dr Syed Ahmed, senior healthcare industry analyst, said: “We estimate that $15 to $20bn worth of drugs in this segment will lose patent protection in the next five to seven years. Patients will benefit from cheaper generic products, while pharmaceutical companies have an opportunity to launch efficacious products to cater for several unmet needs in this market.”  

Visiongain forecasts that the overall asthma and COPD therapies market will grow steadily to 2021. Patients, healthcare providers and drug developers will benefit from new treatments, answering the therapeutic challenges, the report concludes. This new study adds to visiongain’s wide range of analytical reports in healthcare and other industry areas.  

For sample pages of this report please click on:

www.visiongain.com/Report/658/Asthma-and-COPD-Therapies-World-Market-2011-2021

Table of Contents
1. Executive Summary
1.1 Asthma & COPD Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to Asthma & COPD Therapies
2.1 Introduction
2.1.1 The Asthma & COPD Market
2.2 Overview of Respiratory Disorders
2.3 Asthma
2.3.1 Causes and Triggers of Asthma
2.3.2 Increasing Prevalence
2.3.3 High Economic Cost
2.3.4 Treatments for Asthma
2.3.5 Delivery Method - Types of Inhaler
2.4 Chronic Obstructive Pulmonary Disease (COPD)
2.4.1 Symptoms of COPD
2.4.2 Management of COPD
2.4.3 COPD on the Rise
2.4.4 The Economic Burden of COPD
2.5 Major Drug Classes in Treating Respiratory Diseases
2.5.1 Combination Drugs
2.5.2 Leukotriene Inhibitors
2.5.3 Corticosteroids
2.5.4 Beta-2 (Adrenoreceptor) Agonists
2.5.5 Antihistamines
2.5.6 Monoclonal Antibodies

3. The Asthma & COPD Therapies Market, 2011-2021
3.1 The World Asthma & COPD Therapies Market in 2010
3.2 Growing Market for Asthma & COPD Drug Treatments
3.2.1 Sales Forecast for Asthma & COPD Therapies, 2011-2015
3.3 Leading Companies in Asthma & COPD Therapies Market
3.3.1 GSK Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
3.3.2 GSK Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
3.3.3 Merck Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
3.3.4 Merck Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
3.3.5 Boehringer Ingelheim Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
3.3.6 Boehringer Ingelheim Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
3.3.7 AstraZeneca Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
3.3.8 AstraZeneca Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
3.3.9 Novartis Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
3.3.10 Novartis Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
3.3.11 Nycomed Sales Forecast for Asthma & COPD Therapies Market, 2011-2015
3.3.12 Nycomed Sales Forecast for Asthma & COPD Therapies Market, 2016-2021
3.3.13 Summary: Leading Companies in Asthma & COPD Therapies Market, 2011-2021
3.4 Asthma & COPD Therapies: Leading National Markets, 2011-2021
3.4.1 The US Asthma & COPD Therapies Market, 2011-2021
3.4.2 The Japanese Asthma & COPD Therapies Market, 2011-2021
3.4.3 The Leading European Asthma & COPD Therapies Markets, 2011-2021
3.4.4 Emerging-Economy Asthma & COPD Therapies Markets
3.4.5 The Chinese Asthma & COPD Therapies Market, 2011-2021
3.4.6 The Indian Asthma & COPD Therapies Market, 2011-2021
3.5 Summary of Market Forecasts

4. GlaxoSmithKline’s Contribution to the Asthma & COPD Market
4.1 Introduction
4.2 Leading Products
4.3 Sales Forecasts for Leading Products, 2011-2021
4.3.1 Seretide/Advair: Sales, 2010
4.3.1.1 Seretide/Advair: Sales Forecast, 2011-2015
4.3.1.2 Seretide/Advair: Sales Forecast, 2016-2021
4.3.2 Flixotide/Flovent
4.3.2.1 Flixotide/Flovent Sales Forecast, 2011-2015
4.3.2.2 Flixotide/Flovent Sales Forecast, 2016-2021
4.3.3 Ventolin
4.3.3.1 Ventolin Sales Forecast, 2011-2015
4.3.3.2 Ventolin Sales Forecast, 2016-2021
4.3.4 Serevent
4.3.4.1 Serevent Sales Forecast, 2011-2015
4.3.4.2 Serevent Sales Forecast, 2016-2021
4.3.5 Summary: GSK Asthma & COPD Therapies: Sales, 2011-2021
4.4 GSK Asthma & COPD Pipeline Products, 2011
4.5 Summary: GSK Dominates Asthma & COPD Market

5. Merck’s Contribution to the Asthma & COPD Market
5.1 Introduction
5.2 Leading Products
5.3 Sales Forecasts for Leading Products, 2011-2021
5.3.1 Singulair: Sales, 2010
5.3.1.1 Competitors from Other Drug Categories
5.3.1.2 Singulair and Safety Concerns
5.3.1.3 Singulair Patent Expiry Looms for Merck
5.3.1.4 Singulair Sales Forecast, 2011-2015
5.3.1.5 Singulair Sales Forecast, 2016-2021
5.3.2 Proventil HFA
5.3.2.1 Proventil HFA Sales Forecast, 2011-2015
5.3.2.2 Proventil HFA Sales Forecast, 2016-2021
5.3.3 Asmanex Twisthaler
5.3.3.1 Asmanex Twisthaler: Sales Forecast, 2011-2015
5.3.3.2 Asmanex Twisthaler: Sales Forecast, 2016-2021
5.3.4 Summary: Merck Asthma & COPD Therapies: Sales, 2011-2021
5.4 Merck Asthma & COPD Pipeline Products, 2011
5.5 Summary: Merck Reliant on Singulair in Asthma & COPD Market

6. Boehringer Ingelheim’s Contribution to the Asthma & COPD Market
6.1 Introduction
6.2 Leading Products
6.3 Sales Forecasts for Leading Products, 2011-2021
6.3.1 Spiriva Demonstrates Strong Growth, 2010
6.3.1.1 Safety Concerns and the UPLIFT Trial
6.3.1.2 Results of the POET Study
6.3.1.3 Competition and Other Restraints
6.3.1.4 Spiriva: Sales Forecast, 2011-2015
6.3.1.5 Spiriva: Sales Forecast, 2016-2021
6.3.2 Combivent
6.3.2.1 Will the Leading Position Last?
6.3.2.2 Combivent Sales Forecast, 2011-2015
6.3.2.3 Combivent Sales Forecast, 2016-2021
6.3.3 Summary: Boehringer Ingelheim Asthma & COPD Therapies: Sales, 2011-2021
6.4 Boehringer Ingelheim Asthma & COPD Pipeline Products, 2011
6.5 Summary: Boehringer Ingelheim - Strong Presence in the Asthma & COPD Market

7. AstraZeneca’s Contribution to the Asthma & COPD Market
7.1 Introduction
7.2 Leading Products
7.3 Sales Forecasts for Leading Products, 2011-2021
7.3.1 Symbicort: Leading the Market, 2010
7.3.1.1 Symbicort and the COPD Indication
7.3.1.2 Symbicort: The SMART Concept
7.3.1.3 Symbicort: Sales Forecast, 2011-2015
7.3.1.4 Symbicort: Sales Forecast, 2016-2021
7.3.2 Pulmicort
7.3.2.1 Delivery Methods
7.3.2.2 Challenges for Pulmicort: Are They Insurmountable?
7.3.2.3 Pulmicort Sales Forecast, 2011-2015
7.3.2.4 Pulmicort Sales Forecast, 2016-2021
7.3.3 Summary: AstraZeneca Asthma & COPD Therapies: Sales, 2011-2021
7.4 AstraZeneca Asthma & COPD Pipeline Products, 2011
7.5 Summary: AstraZeneca Hopes to Build on Symbicort in Asthma & COPD Market

8. Novartis’ Contribution to the Asthma & COPD Market
8.1 Introduction
8.2 Leading Products
8.3 Sales Forecasts for Leading Products, 2011-2021
8.3.1 Xolair Exhibits Strong Growth, 2010
8.3.1.1 Xolair Sales Forecast, 2011-2015
8.3.1.2 Xolair Sales Forecast, 2016-2021
8.3.2 Onbrez Breezhaler
8.3.2.1 US Launch Under Brand Name Arcapta Neohaler Expected in 2011
8.3.2.2 Onbrez Breezhaler Sales Forecast, 2011-2015
8.3.2.3 Onbrez Breezhaler Sales Forecast, 2016-2021
8.3.3 Summary: Novartis Asthma & COPD Therapies: Sales, 2011-2021
8.4 Novartis Asthma & COPD Pipeline Products, 2011
8.5 Summary: Novartis - Growing Presence in Asthma & COPD Market

9. SWOT Analysis: Factors Influencing the Market
9.1 Introduction
9.2 Asthma & COPD Therapeutics: A Key Sector in Respiratory Diseases
9.3 Commercial Drivers of the Asthma Therapies Market
9.3.1 Expanding Patient Population
9.3.2 High Economic Costs of Respiratory Diseases
9.3.3 Changing Perception of COPD
9.3.4 Educating the Masses: Understanding the Severity of Respiratory Disease
9.3.5 Management Rather than Cure
9.3.6 Lifecycle Management Strategies to Counter Patent Expiry
9.3.7 Brand Awareness
9.3.8 Inhalable Systems: DPI and pMDI Gain Momentum
9.4 Principal Restraints for Respiratory Therapeutics
9.4.1 The Threat of Generics
9.4.2 Restrictions on Healthcare Budgets Favour the Use of Generics
9.4.3 Purchasers Hold Increased Bargaining Power
9.4.4 Maturation of the Market
9.5 Research Interview: Dr Barbara Yawn, MD, Director of Research, Olmsted Medical Center, and Adjunct Professor, Department of Family and Community Health, University of Minnesota, USA
9.5.1 On Key Unmet Needs
9.5.2 Asthma/COPD R&D Focus in the Future
9.5.3 Main Challenges Facing Asthma & COPD Research
9.5.4 Advantages & Disadvantages of Current Asthma & COPD Therapies
9.5.5 On Important Developments in the Sector
9.5.6 On Pipeline Developments in Asthma & COPD
9.6 Summary of Chapter: Market Drivers and Restraints

10. Conclusions from Our Study
10.1 Introduction
10.2 Leading Companies in the Market
10.3 Leading Products in Asthma and COPD Market, 2010
10.4 Combination Drugs Such as Seretide/Advair Continue to Dominate
10.5 Addressing Unmet Needs Offers Potential for Revenue Growth
10.6 Concluding Remarks

List of Tables
Table 2.1 Common Respiratory Diseases
Table 2.2 Causes of Asthma
Table 2.3 Asthma Triggers
Table 2.4 Symptoms of COPD
Table 3.1 Asthma & COPD Market: World Sales Forecast, 2010-2015
Table 3.2 Asthma & COPD Market: World Sales Forecast, 2016-2021
Table 3.3 GSK: Asthma & COPD Therapies Sales Forecast, 2010-2015
Table 3.4 GSK: Asthma & COPD Therapies Sales Forecast, 2016-2021
Table 3.5 Merck: Asthma & COPD Therapies Sales Forecast, 2010-2015
Table 3.6 Merck: Asthma & COPD Therapies Sales Forecast, 2016-2021
Table 3.7 Boehringer Ingelheim: Asthma & COPD Therapies Sales Forecast, 2010-2015
Table 3.8 Boehringer Ingelheim: Asthma & COPD Therapies Sales Forecast, 2016-2021
Table 3.9 AstraZeneca: Asthma & COPD Therapies Sales Forecast, 2010-2015
Table 3.10 AstraZeneca: Asthma & COPD Therapies Sales Forecast, 2016-2021
Table 3.11 Novartis: Asthma & COPD Therapies Sales Forecast, 2010-2015
Table 3.12 Novartis: Asthma & COPD Therapies Sales Forecast, 2016-2021
Table 3.13 Nycomed: Asthma & COPD Therapies Sales Forecast, 2010-2015
Table 3.14 Nycomed: Asthma & COPD Therapies Sales Forecast, 2016-2021
Table 3.15 Leading Companies: Asthma & COPD Therapies Sales Forecasts, 2010-2015
Table 3.16 Leading Companies: Asthma & COPD Therapies Sales Forecasts, 2016-2021
Table 3.17 Leading Asthma & COPD Therapies National Market Forecasts, 2010-2021
Table 4.1 Seretide/Advair Sales Forecast, 2010-2015
Table 4.2 Seretide/Advair Sales Forecast, 2016-2021
Table 4.3 Flixotide/Flovent Sales Forecast, 2010-2015
Table 4.4 Flixotide/Flovent Sales Forecast, 2016-2021
Table 4.5 Ventolin Sales Forecast, 2010-2015
Table 4.6 Ventolin Sales Forecast, 2016-2021
Table 4.7 Serevent Sales Forecast, 2010-2015
Table 4.8 Serevent Sales Forecast, 2016-2021
Table 4.9 GSK Asthma & COPD Sales Forecast, 2010-2015
Table 4.10 GSK Asthma & COPD Sales Forecast, 2016-2021
Table 4.11 GSK Asthma & COPD Pipeline Products, 2011
Table 5.1 Singulair Sales Forecast, 2010-2015
Table 5.2 Singulair Sales Forecast, 2016-2021
Table 5.3 Proventil HFA Sales Forecast, 2010-2015
Table 5.4 Proventil HFA Sales Forecast, 2016-2021
Table 5.5 Asmanex Twisthaler Sales Forecast, 2010-2015
Table 5.6 Asmanex Twisthaler Sales Forecast, 2016-2021
Table 5.7 Merck Asthma & COPD Sales Forecast, 2010-2015
Table 5.8 Merck Asthma & COPD Sales Forecast, 2016-2021
Table 5.9 Merck Asthma & COPD Pipeline Products, 2011
Table 6.1 Spiriva Sales Forecast, 2010-2015
Table 6.2 Spiriva Sales Forecast, 2016-2021
Table 6.3 Combivent Sales Forecast, 2010-2015
Table 6.4 Combivent Sales Forecast, 2016-2021
Table 6.5 Boehringer Ingelheim Asthma & COPD Sales Forecast, 2010-2015
Table 6.6 Boehringer Ingelheim Asthma & COPD Sales Forecast, 2016-2021
Table 7.1 Symbicort Sales Forecast, 2010-2015
Table 7.2 Symbicort Sales Forecast, 2016-2021
Table 7.3 Pulmicort Sales Forecast, 2010-2015
Table 7.4 Pulmicort Sales Forecast, 2016-2021
Table 7.5 AstraZeneca Asthma & COPD Sales Forecast, 2010-2015
Table 7.6 AstraZeneca Asthma & COPD Sales Forecast, 2016-2021
Table 8.1 Xolair Sales Forecast, 2010-2015
Table 8.2 Xolair Sales Forecast, 2016-2021
Table 8.3 Onbrez Breezhaler Sales Forecast, 2010-2015
Table 8.4 Onbrez Breezhaler Sales Forecast, 2016-2021
Table 8.5 Novartis Asthma & COPD Sales Forecast, 2010-2015
Table 8.6 Novartis Asthma & COPD Sales Forecast, 2016-2021
Table 8.7 Novartis Asthma & COPD Pipeline, 2011
Table 9.1 SWOT Analysis of World Asthma & COPD Therapies Market: Strengths & Weaknesses, 2011-2021
Table 9.2 SWOT Analysis of World Asthma & COPD Therapies Market: Opportunities & Threats, 2011-2021
Table 10.1 Asthma & COPD Market: World Sales Forecasts, 2010, 2012, 2015, 2017, 2019 and 2021
Table 10.2 Asthma & COPD Market: Top Ten Products - Sales and Market Shares, 2010

List of Figures
Figure 3.1 Asthma & COPD Market: World Sales Forecast, 2010-2015
Figure 3.2 Asthma & COPD Market: World Sales Forecast, 2016-2021
Figure 3.3 GSK: Asthma & COPD Therapies Sales Forecast, 2010-2015
Figure 3.4 GSK: Asthma & COPD Therapies Sales Forecast, 2016-2021
Figure 3.5 Merck: Asthma & COPD Therapies Sales Forecast, 2010-2015
Figure 3.6 Merck: Asthma & COPD Therapies Sales Forecast, 2016-2021
Figure 3.7 Boehringer Ingelheim: Asthma & COPD Therapies Sales Forecast, 2010-2015
Figure 3.8 Boehringer Ingelheim: Asthma & COPD Therapies Sales Forecast, 2016-2021
Figure 3.9 AstraZeneca: Asthma & COPD Therapies Sales Forecast, 2010-2015
Figure 3.10 AstraZeneca: Asthma & COPD Therapies Sales Forecast, 2016-2021
Figure 3.11 Novartis: Asthma & COPD Therapies Sales Forecast, 2010-2015
Figure 3.12 Novartis: Asthma & COPD Therapies Sales Forecast, 2016-2021
Figure 3.13 Nycomed: Asthma & COPD Therapies Sales Forecast, 2010-2015
Figure 3.14 Nycomed: Asthma & COPD Therapies Sales Forecast, 2016-2021
Figure 3.15 Leading Companies: Asthma & COPD Therapies Sales Forecasts, 2010-2021
Figure 3.16 Leading Companies: Asthma & COPD Therapies Market Shares, 2010
Figure 3.17 Leading National Asthma & COPD Market Forecasts, 2010-2021
Figure 3.18 National Asthma & COPD Market Forecasts: Lower Range, 2010-2021
Figure 3.19 Asthma & COPD Therapies: Sales in Leading National Markets, 2010
Figure 3.20 Asthma & COPD Therapies: Sales in Leading National Markets, 2015
Figure 3.21 Asthma & COPD Therapies: Sales in Leading National Markets, 2018
Figure 3.22 Asthma & COPD Therapies: Sales in Leading National Markets, 2021
Figure 4.1 Seretide/Advair Sales Forecast, 2010-2021
Figure 4.2 Flixotide/Flovent Sales Forecast, 2010-2021
Figure 4.3 Ventolin Sales Forecast, 2010-2021
Figure 4.4 Serevent Sales Forecast, 2010-2021
Figure 4.5 GSK Asthma & COPD Sales Forecast, 2010-2021
Figure 4.6 GSK: Leading Asthma & COPD Drugs Sales Forecast, 2010-2021
Figure 5.1 Singulair Sales Forecast, 2010-2021
Figure 5.2 Proventil HFA Sales Forecast, 2010-2021
Figure 5.3 Asmanex Twisthaler Sales Forecast, 2010-2021
Figure 5.4 Merck Asthma & COPD Drugs Sales Forecast, 2010-2021
Figure 5.5 Merck Asthma & COPD Drugs Sales Forecast, 2010-2021
Figure 6.1 Spiriva Sales Forecast, 2010-2021
Figure 6.2 Combivent Sales Forecast, 2010-2021
Figure 6.3 Boehringer Ingelheim Asthma & COPD Sales Forecast, 2010-2021
Figure 6.4 Boehringer Ingelheim Asthma & COPD Drugs Sales Forecast, 2010-2021
Figure 7.1 Symbicort Sales Forecast, 2010-2021
Figure 7.2 Pulmicort Sales Forecast, 2010-2021
Figure 7.3 AstraZeneca Asthma & COPD Sales Forecast, 2010-2021
Figure 7.4 AstraZeneca Asthma & COPD Drugs Sales Forecast, 2010-2021
Figure 8.1 Xolair Sales Forecast, 2010-2021
Figure 8.2 Onbrez Breezhaler Sales Forecast, 2010-2021
Figure 8.3 Novartis Asthma & COPD Sales Forecast, 2010-2021
Figure 8.4 Novartis Asthma & COPD Drugs Sales Forecast, 2010-2021
Figure 10.1 Asthma & COPD Market: World Sales Forecast, 2010-2021
Figure 10.2 Asthma & COPD: Sales Forecasts for Leading Companies, 2010-2021 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Pharmaceutical, Telecoms, Energy, Defence and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

Please contact Sara Peerun for an exec summary:
Email: Sara.peerun@visiongainglobal.com
Tel: +44-0207-3366100
Web: www.visiongain.com

.